S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
FLNA · Filana Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Filana Therapeutics Inc (FLNA)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$0.66
-0.03
(-4.59%)
● At close: October 21 at 4:00:00 PM EDT
$0.66
+0.00
(+0.11%)
Overnight:
12:28:08 AM EDT
DAY'S RANGE
$0.66
$0.65
$0.70
52-WEEK RANGE
$0.66
$0.67
$2.27
What's happening
- FLNA is down 4.59% today, trading at $0.66. — Live quote
- It's trading within 3% of its 52-week low ($0.67). (Finnhub fundamentals)
- Volume today (2,169) is well below its 3-month average of 1,543,630. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.22 actual vs. $-0.28 estimated (+20.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-03-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
FLNA
-67.06%
vs S&P 500
-80.77%
6-MONTH RETURN
FLNA
-60.88%
3-MONTH RETURN
FLNA
-31.83%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2025-10-26 (Q3 2025)
$-0.22
Est. $-0.28
BEAT +20.1%
2025-04-26 (Q1 2025)
$-0.48
Est. $—
2025-01-26 (Q4 2024)
$-0.57
Est. $-0.67
BEAT +14.7%
2024-10-26 (Q3 2024)
$-0.58
Est. $-0.90
BEAT +35.4%
Valuation Measures & Ratios
Enterprise Value4-$49.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.81
Price / Book70.90
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin76.73%
Operating Margin76.26%
Return on Equity (ROE8)-58.78%
Return on Assets (ROA9)-36.74%
Avg Volume (3M)1,543,630
Quarterly history (5 periods)
| Measure | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 |
|---|---|---|---|---|---|
| Market cap | — | $142.5M | $87.2M | $73.6M | — |
| P/E | — | -1.34 | -0.98 | -3.65 | — |
| Price/Book | — | 1.75 | 0.99 | 0.58 | — |
| ROE | — | -130.42% | -101.64% | -15.79% | — |
| ROA | — | -82.00% | -66.05% | -14.30% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,885,540
Change from Prior Settlement-5.35%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Net profit margin is 76.7%. Finnhub fundamentals ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on FLNA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$11.2M | -$11.9M | -$45.4M | -$24.6M | -$30.6M | -$61.4M | -$19.9M | -$27.9M |
| Net income | -$10.3M | -$10.8M | -$44.2M | -$23.4M | -$27.9M | $6.2M | $25.0M | -$25.7M |
| EPS (diluted) | — | $-0.22 | $-0.92 | $-0.48 | $-0.58 | $0.13 | $-0.43 | $-0.61 |
| EPS (basic) | $-0.21 | $-0.22 | $-0.92 | $-0.48 | $-0.58 | $0.13 | $0.58 | $-0.61 |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $108.4M | $118.4M | $129.7M | $135.4M | $140.9M | $157.5M | $223.8M | $243.6M |
| Total liabilities | $40.2M | $44.0M | $48.2M | $47.4M | $13.3M | $11.8M | $57.1M | — |
| Stockholders' equity | $68.1M | $74.4M | $81.6M | $88.0M | $127.6M | $145.7M | $166.6M | $189.0M |
| Total current assets | $88.0M | $97.7M | $108.9M | $114.8M | $120.2M | $136.5M | $202.5M | $222.1M |
| Total current liabilities | $40.1M | $43.8M | $48.0M | $47.3M | $13.2M | $11.8M | $57.0M | $54.6M |
| Cash & equivalents | $86.6M | $95.5M | $106.1M | $112.4M | $117.3M | $128.6M | $149.0M | $207.3M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $220.0K | $64.0K | $106.0K | $134.0K | $162.0K | $38.0K | $192.0K | $161.0K |
| Property, plant & equipment | $20.4M | $20.6M | $20.8M | $20.6M | $20.8M | $21.0M | $21.1M | $21.4M |
| Intangible assets | — | $193.0K | — | — | — | $37.0K | $69.0K | $82.0K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $75.0K | $198.0K | $226.0K | $159.0K | $113.0K | $299.0K | $297.0K | $228.0K |
| Other non-current liabilities | $111.0K | $118.0K | $119.0K | $79.0K | $79.0K | $79.0K | $80.0K | — |
| Common stock & paid-in capital | $48.0K | $48.0K | $48.0K | $48.0K | $48.0K | $48.0K | $48.0K | $48.0K |
| Retained earnings | -$506.4M | -$496.1M | -$483.5M | -$472.7M | -$428.5M | -$405.1M | -$377.5M | -$349.6M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.9M | -$9.7M | -$6.2M | -$4.9M | -$11.3M | -$61.3M | -$18.3M | -$18.2M |
| Investing cash flow | — | -$501.0K | -$80.0K | $0 | $0 | -$57.0K | -$17.0K | -$29.0K |
| Financing cash flow | -$51.0K | -$329.0K | $0 | $0 | $90.0K | $918.0K | $0 | $101.4M |
| Free cash flow | — | -$10.2M | -$6.3M | -$4.9M | -$11.3M | -$61.3M | -$18.3M | -$18.3M |
| Capital expenditures | — | $501.0K | $80.0K | $0 | $0 | $57.0K | $17.0K | $29.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $4.1M | $5.4M | $4.4M | $4.6M | $5.2M | $5.7M | $5.6M | $2.6M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | — | $34.0M | — | — | — | -$2.9M | — | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$95.4M | -$141.4M | -$106.0M | -$80.0M | -$32.9M |
| Net income | -$91.0M | -$24.3M | -$97.2M | -$76.2M | -$32.4M |
| EPS (diluted) | $-1.88 | $-1.46 | $-2.32 | $-1.90 | — |
| EPS (basic) | $-1.88 | $-0.53 | $-2.32 | $-1.90 | $-0.82 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $118.4M | $157.5M | $151.7M | $234.8M | $266.8M |
| Total liabilities | $44.0M | $11.8M | $14.2M | $7.3M | $12.9M |
| Stockholders' equity | $74.4M | $145.7M | $137.5M | $227.5M | $253.9M |
| Total current assets | $97.7M | $136.5M | $129.6M | $211.2M | $244.5M |
| Total current liabilities | $43.8M | $11.8M | $14.2M | $7.1M | $12.5M |
| Cash & equivalents | $95.5M | $128.6M | $121.1M | $201.0M | $233.4M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other current assets | $64.0K | $38.0K | $287.0K | $160.0K | — |
| Property, plant & equipment | $20.6M | $21.0M | $21.9M | $22.9M | $20.6M |
| Intangible assets | $193.0K | $37.0K | $176.0K | $622.0K | $1.1M |
| Other non-current assets | — | — | — | — | $399.0K |
| Accounts payable | — | — | — | $4.0M | $7.1M |
| Accrued liabilities | — | — | — | $2.3M | $2.8M |
| Deferred revenue (current) | — | — | — | — | — |
| Other current liabilities | $198.0K | $299.0K | $385.0K | $492.0K | $631.0K |
| Other non-current liabilities | $118.0K | $79.0K | $0 | $197.0K | $194.0K |
| Common stock & paid-in capital | $48.0K | $48.0K | $42.0K | $42.0K | $40.0K |
| Retained earnings | -$496.1M | -$405.1M | -$380.8M | -$283.6M | -$207.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$32.3M | -$116.9M | -$82.0M | -$77.5M | -$30.2M |
| Investing cash flow | -$581.0K | -$103.0K | -$414.0K | -$2.7M | -$22.2M |
| Financing cash flow | -$239.0K | $124.5M | $2.6M | $47.8M | $192.3M |
| Free cash flow | -$32.8M | -$117.0M | -$82.4M | -$80.2M | -$52.4M |
| Capital expenditures | $581.0K | $103.0K | $414.0K | $2.7M | $22.2M |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $19.6M | $16.3M | $4.6M | $2.1M | $1.8M |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | $34.0M | -$2.9M | $6.9M | -$3.4M | $6.2M |
| Purchases of investments | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding FLNA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-11-29 to 2026-09-30
Recent transactions
- Insiders have net bought 399,904 shares over the last 182 days, across 3 purchases and 0 sales.
- Most recent: Barry Richard (President & CEO) — Open market purchase of 100,000 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)399,904 sh(3 txns)
Sales (open market)0 sh(0 txns)
Net Shares+399,904
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Barry Richard | President & CEO | Open market purchase | 2026-09-30 | 100,000 |
| Anderson Robert Eugene Jr | Director | Open market purchase | 2025-11-24 | 8,600 |
| Cook Robert Christopher | Chief Operating & Legal Office | Open market purchase | 2025-09-30 | 13,725 |
| Kupiec James William | Chief Medical Officer | Open market sale | 2024-11-29 | 4,000 |
| Schoen Eric | Chief Financial Officer | Option exercise | 2024-11-29 | 50,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Barry Richard | President & CEO | Open market purchase | 100,000 | $0.92 |
| 2026-09-29 | Barry Richard | President & CEO | Open market purchase | 206,813 | $0.90 |
| 2026-09-28 | Barry Richard | President & CEO | Open market purchase | 93,091 | $0.84 |
| 2025-11-24 | Anderson Robert Eugene Jr | Director | Open market purchase | 8,600 | $2.90 |
| 2025-11-20 | Barry Richard | President & CEO | Open market purchase | 150,000 | $2.76 |
| 2025-11-19 | Barry Richard | President & CEO | Open market purchase | 73,385 | $2.75 |
| 2025-09-30 | Cook Robert Christopher | Chief Operating & Legal Office | Open market purchase | 13,725 | $2.91 |
| 2025-09-22 | Barry Richard | President & CEO | Open market purchase | 7,172 | $2.28 |
| 2025-09-19 | Barry Richard | President & CEO | Open market purchase | 400 | $2.25 |
| 2025-09-19 | Barry Richard | President & CEO | Open market purchase | 46,908 | $2.29 |
| 2025-09-18 | Barry Richard | President & CEO | Open market purchase | 5,400 | $2.13 |
| 2025-09-18 | Barry Richard | President & CEO | Open market purchase | 185,233 | $2.24 |
| 2024-11-29 | Kupiec James William | Chief Medical Officer | Open market sale | 4,000 | $3.87 |
| 2024-11-29 | Schoen Eric | Chief Financial Officer | Option exercise | 50,000 | $1.18 |
| 2024-11-29 | Schoen Eric | Chief Financial Officer | Open market sale | 2,000 | $3.82 |
| 2024-11-29 | Schoen Eric | Chief Financial Officer | Open market sale | 59,800 | $3.86 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:36 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-20 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-09-30 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-18 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-07-29 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
| 2026-04-28 | 8-K | 2026-04-22 | View on SEC.gov → |
| 2026-03-12 | 10-K | 2025-12-31 | View on SEC.gov → |
Recent news
Headlines about FLNA (Filana Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Fifth Circuit vacates class certification in Filana Therapeutics securities case By Investing.com
Investing.com Nigeria · 2026-10-20 -
Form 8K Filana Therapeutics For: 20 October By Investing.com
Investing.com Nigeria · 2026-10-20 -
Filana Therapeutics Announces Fifth Circuit Rules Texas District Court Misapplied Legal Standard In Class Certification
Benzinga · 2026-10-20 -
FLNA Jan 2028 0.500 put (FLNA280121P00000500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19 -
Filana Therapeutics, Inc. (FLNA) Stock Price Prediction for 2026, 2030-2040
Traders Union · 2026-10-17 -
FLNA280121P00001500 Interactive Stock Chart | FLNA Jan 2028 1.500 put Stock - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Yahoo · 2026-10-09 -
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Yahoo Finance · 2026-09-22
No headlines in this category right now — try “All”.